Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $84.15 | Total: $420.75 |
| 1 | 10 | $71.28 | Total: $712.80 |
| 1 | 25 | $60.39 | Total: $1,509.75 |
| 1 | 50 | $51.48 | Total: $2,574.00 |
| 1 | 100 | $44.55 | Total: $4,455.00 |
Overview
EC359 is a potent and selective inhibitor of leukemia inhibitory factor receptor (LIFR), a potent inhibitor with anticancer activity, blocks LIFLIFR interaction, and can be used in the study of leukemia and endometrial cancer.
Chemical Properties
| Molecular Formula | C36H38F2O2 |
| Molecular Weight | 540.68 |
| CAS Numbers | 2012591-09-0 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | [H][C@@]12CC[C@@](O)(C(F)(F)C#C)[C@@]1(C)C[C@@H](C1=C3CCC(=O)C=C3CC[C@@]21[H])c1ccc(cc1)-c1c(C)cc(C)cc1C |
Storage and Handling
0C Short Term, -20C Long Term
References
Viswanadhapalli S, et al. EC359 A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer. Mol Cancer Ther. 2019 Aug;18[8] 1341-1354.